Biotin safety studies
Pro Research Analysisby 
Searched over 200M research papers
Biotin Safety in Clinical and Preclinical Studies
High-Dose Biotin Safety in Multiple Sclerosis Patients
Several clinical trials have evaluated the safety of high-dose biotin (MD1003) in patients with progressive multiple sclerosis. In a large, randomized, double-blind, placebo-controlled phase 3 trial, the incidence of treatment-emergent adverse events was similar between the biotin and placebo groups (84% vs. 85%), and the rate of serious adverse events was also comparable (26% in both groups). Only one death occurred in the biotin group, and none in the placebo group. However, the study highlighted a significant safety concern: high-dose biotin led to inaccurate laboratory results for tests using biotinylated antibodies, which could have deleterious health consequences due to misdiagnosis or inappropriate treatment decisions . Another double-blind, placebo-controlled study confirmed that high-dose biotin was generally well tolerated, with a safety profile similar to placebo . A pilot study also reported no major safety issues with high-dose biotin in progressive MS patients .
Preclinical Toxicology and Safety of Biotin Salts
Preclinical studies on a novel, highly soluble biotin salt, magnesium biotinate (MgB), found no evidence of mutagenicity, clastogenicity, or aneugenicity in in vitro tests. Acute and repeat-dose oral toxicity studies in rats showed no adverse effects, and the compound was considered safe at the tested doses . Another animal study demonstrated that MgB was well absorbed and did not cause any changes in safety blood panel measurements or observable adverse effects, supporting its safety and bioavailability .
Biotin Interference with Laboratory Tests
A major safety issue with high-dose biotin supplementation is its interference with laboratory immunoassays, especially those using biotin-streptavidin technology. This can result in falsely high or low results for tests such as thyroid function, reproductive hormones, and cardiac markers, potentially leading to misdiagnosis Cree2020Johnson2019Strilić2024. While real-world studies show that biotin interference is rare in the general population, the risk is higher in patients taking high-dose biotin, such as those with multiple sclerosis . Strategies to mitigate this risk include biotin depletion protocols, serial dilution, and the development of biotin-resistant immunoassays Johnson2019Strilić2024.
Other Safety Considerations
High-dose biotin appears to be generally well tolerated in humans, with rapid absorption and urinary excretion. However, animal studies have raised concerns about possible teratogenicity at very high doses, though data are limited . Continued research is needed to fully understand the long-term safety of high-dose biotin, especially in special populations.
Conclusion
Overall, biotin—both in standard and high-dose forms—shows a favorable safety profile in clinical and preclinical studies, with adverse event rates similar to placebo. The most significant safety concern is interference with laboratory tests, which can lead to misdiagnosis and inappropriate treatment. Awareness among healthcare providers and improvements in laboratory assay design are essential to mitigate these risks. Further research is warranted to clarify long-term safety, especially at very high doses and in specific patient groups.
Sources and full results
Most relevant research papers on this topic
Toxicologic evaluation of a novel, highly soluble biotin salt, magnesium biotinate.
Magnesium biotinate (MgB) is not mutagenic, clastogenic, or aneugenic, and has a low LD50 in oral doses in Sprague-Dawley rats.
DOI